Entera Bio (ENTX) Return on Sales (2019 - 2025)
Entera Bio's (ENTX) quarterly Return on Sales came in at 2.84% in Q4 2025, down 255.0% YoY from 1.83% in Q4 2024, and down 215.91% on a QoQ basis from 0.9% in Q3 2025.
Entera Bio (ENTX) Return on Sales (2019 - 2025) Analysis & Trends
Entera Bio (ENTX) has 7 years of Return on Sales data on file, last reported at 2.84% in Q4 2025.
- Quarterly Return on Sales fell 255.0% year-over-year to 2.84% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2.84% (down 229.0% YoY) and the FY2025 annual result came in at 2.72%, down 220.0% from the prior year.
- Return on Sales fell to 2.84% in Q4 2025, from 0.9% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.15% in Q1 2021 to a low of 7.09% in Q3 2023.
- A 5-year average of 1.57% and a median of 0.68% in 2024 frame the typical range for Return on Sales.
- Annual changes were most pronounced in 2023 — Return on Sales plunged 410 bps — and 2024, when it jumped 637 bps.
- Tracing ENTX's Return on Sales over 5 years: stood at 0.25% in 2021, then slumped by 772 bps to 2.17% in 2022, then slumped by 227 bps to 7.09% in 2023, then surged by 96 bps to 0.29% in 2024, then tumbled by 887 bps to 2.84% in 2025.
- The last three Return on Sales figures came in at 2.84% (Q4 2025), 0.9% (Q3 2025), and 0.65% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.84% |
| Sep 30, 2025 | -0.90% |
| Jun 30, 2025 | -0.65% |
| Mar 31, 2025 | -0.62% |
| Dec 31, 2024 | -0.29% |
| Sep 30, 2024 | -0.72% |
| Jun 30, 2024 | -0.43% |
| Sep 30, 2023 | -7.09% |
| Jun 30, 2023 | -4.83% |
| Mar 31, 2023 | -1.74% |
| Dec 31, 2022 | -2.17% |
| Sep 30, 2022 | -3.83% |
| Jun 30, 2022 | -0.72% |
| Mar 31, 2022 | -0.56% |
| Dec 31, 2021 | -0.25% |
| Sep 30, 2021 | -0.23% |
| Jun 30, 2021 | -0.24% |
| Mar 31, 2021 | -0.15% |
| Jun 30, 2020 | -0.61% |
| Jun 30, 2019 | -0.27% |